Literature DB >> 6201792

Rubeosis iridis: preoperative iris fluorescein angiography and periocular steroids.

M Ehrenberg, B W McCuen, R H Schindler, R Machemer.   

Abstract

To study the risk of developing rubeosis iridis following vitrectomy, the use of preoperative iris fluorescein angiography was prospectively investigated on patients with diabetes mellitus, without any clinically detectable iris or angle neovascularization. With increasing severity of fluorescein leakage, the risk of iris neovascularization with or without glaucoma, six months after vitreous surgery, is significantly increased. It was also determined whether postoperative steroid therapy (periocular triamcinolone acetonide and topical prednisolone phosphate) reduces the risk of developing iris neovascularization after vitrectomy. Controlled and treated patient eyes did not differ significantly in the degree of rubeosis. However, neovascular glaucoma statistically occurred more frequently in the nonsteroid group.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6201792     DOI: 10.1016/s0161-6420(84)34292-0

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


  8 in total

1.  Regression of rubeosis in the fellow eye after intravitreal ranibizumab injection.

Authors:  Julia Lüke; Khaled Nassar; Salvatore Grisanti; Matthias Lüke
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2012-11-07       Impact factor: 3.117

2.  Biomicroscopy versus fluorescein angiography of the iris in the detection of diabetic iridopathy.

Authors:  F Bandello; R Brancato; R Lattanzio; B Falcomatà; A Malegori
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1993-08       Impact factor: 3.117

3.  Ranibizumab as adjuvant in the treatment of rubeosis iridis and neovascular glaucoma--results from a prospective interventional case series.

Authors:  Julia Lüke; Khaled Nassar; Matthias Lüke; Salvatore Grisanti
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2013-07-28       Impact factor: 3.117

4.  Intravitreal bevacizumab (Avastin) injection for neovascular glaucoma: a survey on 23 cases throughout 12-month follow-up.

Authors:  Ciro Costagliola; Ugo Cipollone; Michele Rinaldi; Michele della Corte; Francesco Semeraro; Mario R Romano
Journal:  Br J Clin Pharmacol       Date:  2008-11       Impact factor: 4.335

5.  Relation between iridopathy and retinopathy in diabetes.

Authors:  F Bandello; R Brancato; R Lattanzio; M Galdini; B Falcomatà
Journal:  Br J Ophthalmol       Date:  1994-07       Impact factor: 4.638

6.  Nonproliferative diabetic retinopathy with significant capillary nonperfusion.

Authors:  J Verdaguer; N le Clercq; J Holuigue; R Musalem
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1987       Impact factor: 3.117

7.  Frequency and Risk Factors for Neovascular Glaucoma After Vitrectomy in Eyes with Diabetic Retinopathy: An Observational Study.

Authors:  Xu Liang; Yue Zhang; Yu-Peng Li; Wan-Rong Huang; Jia-Xing Wang; Xuan Li
Journal:  Diabetes Ther       Date:  2019-07-18       Impact factor: 2.945

8.  Visible Blood Flow in a Case of Rubeosis Iridis.

Authors:  Masaki Tanito; Sho Ichioka; Yuji Takayanagi; Akiko Ishida
Journal:  Case Rep Ophthalmol       Date:  2021-06-03
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.